By Clinical Informatics News Staff 

 

January 15, 2014 | CollabRx and Cynvenio are linking genomics with apps in an extension of their multi-year agreement.  

 

Patients of physicians who order the Cynvenio ClearID Breast Cancer genomic blood test will receive an annual subscription to a customized version of the CollabRx Therapy Finder app for breast cancer. The ClearID test supports the proactive monitoring of breast cancer survivors at high risk of recurrence, such as triple-negative patients (ER-, PR-, HER2-). CollabRx's breast cancer Therapy Finder app is a web-based decision support tool that enables patients (and their physicians) to take into account the molecular aspects of a metastatic breast cancer tumor when determining a treatment plan.

 

"This collaboration will provide breast cancer patients, survivors and their families with two powerful tools in one test," said Andre de Fusco, CEO of Cynvenio in a statement. "The ClearID Breast Cancer test offers genomic insights from a standard blood draw analyzed by next gen sequencing. By pairing ClearID with the CollabRx Therapy Finder we can now take into account an individual patient's molecular (tumor) data when offering the latest insights into breast cancer treatments. This is a milestone in our efforts to develop a new standard for individualized breast cancer monitoring."

 

The Therapy Finder app provides a dynamic user environment to navigate and understand both the current standard of care as well as experimental therapy options with the goal of enabling patients to receive the best possible care. The subscription will include access to news and information to provide patient-oriented educational material on advances in breast cancer medical and scientific research, risk factors for recurrence, monitoring, and early detection. The breast cancer Therapy Finder is kept dynamically up-to-date and curated by CollabRx medical and scientific personnel with the support of an editorial board composed of independent breast cancer clinical experts.

 

CollabRx also hosts Therapy Finders for lung cancer, colorectal cancer, and melanoma.